From development of indigenous vaccines to novel point-of-care diagnostics, India has initiated an integrated response to conquer the unprecedented COVID-19 pandemic, Union minister Harsh Vardhan said on Saturday.
Speaking at the 8th BRICS STI Ministerial Assembly held on Friday, Vardhan said India could also be hosting clinical trials for the entire major vaccines, and approximately 20 vaccines are in different stages of development.
Two of them are in the most advanced stage of development. COVAXIN developed through ICMR-Bharat Biotech collaboration and COVISHIELD from the Serum Institute of India. Both are in Phase-III clinical trial stage, he added.
“India has initiated an integrated response to conquer this unprecedented COVID-19 pandemic.
“From the development of indigenous vaccines, novel point-of-care diagnostics and therapeutic formulations based on traditional knowledge, to establishing research resources and offering products and services, Indian R&D entities, both private and non-private, are working relentlessly to develop effective interventions for combating the pandemic,” Vardhan, who holds the charge of Health Ministry in addition to the Science and Technology Ministry, said.
Valery Falkov, Russian Minister of Science and Higher Education, Marcos Pontes, Brazilian Minister of Science, Technology and Innovation, Huang Wei, First Vice Minister of Science and Technology, China, Bonginkosi Emmanuel Nzimande, South African Minister of Higher Education, Science and Technology and several other dignitaries from member countries participated in the assembly.
Vardhan said more than 100 start-ups have developed innovative products for COVID-19.
He said the government has announced a USD 120 million grant for COVID-19 vaccine research. This is being given for CovidSuraksha (Mission for protection from Covid) and is for use purely for research and development in this field, he said.
“The grant does not cover the actual cost of the vaccine and its distribution expenses, which will be made one by one as and when the vaccine is to be had,” he said.
Vardhan said India could also be hosting clinical trials for the entire major vaccine contenders. Serum Institute of India, the world’s largest vaccine manufacturer, is conducting trials for the vaccine developed by Oxford University, he said.
“One of our pharma giants, Dr Reddy’s Laboratories, will hand out the Russian vaccine in India after conducting final-stage human trials and receiving regulatory approval,” the minister said.
Vardhan said India will actively contribute in implementation of BRICS STI Calendar of Activities 2020-21 and improve continuation of scientific activities under BRICS MOU on Science, Technology and Innovation.
The BRICS member leaders applauded India for the ‘SERBPOWER’ (Promoting Opportunities For Women in Exploratory Research) scheme launched final month, the Branch of Science and Technology said.
“We have recently launched a scheme ‘SERBPOWER’ to encourage and improve emerging in addition to eminent women researchers to undertake R&D activities in areas of science and engineering. We may think of networking BRICS women scientists through a committed platform and mechanism,” he added.
(Only the headline and picture of this outline may have been reworked by the Trade Standard staff; the remainder of the satisfied is auto-generated from a syndicated feed.)
Trade Standard has all the time strived tough to supply up-to-date information and statement on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and fixed feedback on how to enhance our offering have only made our unravel and commitment to these ideals stronger. Even all the way through these difficult times arising out of Covid-19, we continue to remain dedicated to keeping you informed and up to date with credible news, authoritative views and incisive statement on topical issues of relevance.
We, on the other hand, have a request.
As we battle the economic affect of the pandemic, we need your improve even more, in order that we will be able to continue to give you more quality satisfied. Our subscription mannequin has seen an encouraging response from many of you, who have subscribed to our online satisfied. More subscription to our online satisfied can only help us achieve the goals of offering you even better and more applicable satisfied. We imagine in free, reasonable and credible journalism. Your improve through more subscriptions can help us practise the journalism to which we are dedicated.
Make stronger quality journalism and subscribe to Trade Standard.